Oxbryta

Indicated For

sickle cell disease

About This Medication

# Pfizer RxPathways Patient Assistance Program Guide: How to Get Oxbryta (voxelotor) at Low or No Cost **Important Notice: Oxbryta (voxelotor) has been voluntarily withdrawn from all markets worldwide by Pfizer as of September 25, 2024, due to safety concerns including higher rates of vaso-occlusive crises and deaths compared to placebo in postmarketing studies. This guide provides historical information on the former Pfizer RxPathways program for reference, but no new prescriptions or assistance are available. Patients should consult their healthcare provider immediately about alternative treatments for sickle cell disease (SCD).**[7][8][9] ## About Oxbryta and Sickle Cell Disease Oxbryta (voxelotor) was a prescription medicine approved for treating sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. SCD is a genetic blood disorder where red blood cells can become sickle-shaped, blocking blood flow and causing pain crises, anemia, and organ damage. Oxbryta worked by increasing hemoglobin's affinity for oxygen, inhibiting sickle hemoglobin polymerization to reduce sickling and hemolysis (red blood cell destruction).[1][6][7] **Common side effects** included headache, diarrhea, abdominal pain, nausea, rash, and fever. It was taken orally with or without food. However, due to emerging safety data showing risks outweighing benefits, Pfizer halted all lots, clinical trials, and expanded access programs. The FDA advises stopping use and reporting adverse events.[7][8][9] ## Who Qualifies for Pfizer RxPathways? Pfizer RxPathways was Pfizer's patient assistance program offering free medicines like Oxbryta to eligible uninsured or government-underinsured patients (e.g., Medicare, Medicaid). **Commercially insured patients were not eligible.** Key requirements included: - A valid U.S. prescription for an FDA-approved indication (SCD for Oxbryta). - Treatment in an outpatient setting. - U.S. residency (or applicable U.S. territory). - Meeting income guidelines: Typically **500% or 600% of the Federal Poverty Level (FPL)** for specialty/oncology products like Oxbryta, varying by household size and product.[5] **Note:** Exact thresholds depended on annual updates; patients had to provide proof like W-2, pay stubs, or tax returns. Some products required trying other assistance first.[5] ## Income Eligibility Breakdown Eligibility was based on household income relative to FPL. Here's a general table for 2024 500% FPL (adjust for current year and exact program rules; higher limits like 600% applied to some specialty drugs): | Household Size | Annual Income Limit (500% FPL) | |----------------|-------------------------------| | 1 (Individual) | $75,300 | | 2 (Couple) | $101,500 | | 3 | $127,600 | | 4 | $153,800 | *Source: General FPL guidelines; confirm via Pfizer RxPathways for product-specific % (e.g., 500-600%). Larger families add ~$26,200 per person. Eligibility subject to change.*[5] ## Insurance Requirements - **Uninsured or government underinsured only** (Medicare Part D, Medicaid eligible but facing coverage gaps). - **No commercial insurance** – patients with private plans must explore co-pay cards or hubs first via Pfizer Oncology Together (now inactive for Oxbryta).[5][9] - Doctors could help navigate prior authorizations or appeals if insured.[4] ## Step-by-Step Application Process 1. **Get a Prescription:** Obtain from a licensed U.S. healthcare provider for outpatient SCD treatment.[5] 2. **Check Eligibility:** Use Pfizer RxPathways tools or call to verify income/insurance.[5] 3. **Gather Documents:** Proof of income (W-2, stubs, tax return), prescription, proof of residency, ID.[5] 4. **Complete Enrollment:** Doctor/patient submits form online, mail, or fax via pfizerrxpathways.com.[5] 5. **Submit:** Patient Access team reviews; may connect to co-pay/savings if ineligible for free med.[5] 6. **Approval Notification:** Via mail/email/phone.[5] **Historical Contact:** Pfizer RxPathways (details via pfizer.com); now refer to provider for alternatives post-withdrawal.[4][5] ## Timeline and Delivery - **Processing:** 2-4 weeks typically, but urgent cases faster.[5] - **Delivery:** Free medicine shipped to doctor's office or home.[5] - **Supply Duration:** 1-12 months per approval, based on guidelines.[5] ## Alternatives if Denied or Post-Withdrawal - **Other Assistance:** Independent foundations, state programs, or generic SCD treatments (hydroxyurea, blood transfusions, voxelotor biosimilars – none listed).[5] - **SCD Options:** Consult specialist for approved therapies like hydroxyurea, crizanlizumab (Adakveo), or L-glutamine (Endari). Newer gene therapies may apply.[7][10] - **If Denied:** Appeal with more docs, try co-pay programs, or 3rd-party aid via Medicine Access Counselors.[5] - **Post-Withdrawal:** Taper off over ~2 weeks if advised (optional); seek compassionate use unlikely. Report issues to FDA MedWatch.[8][9][10] ## Reauthorization and Refills Annual re-certification with updated income/proof required. Refills auto-processed if eligible.[5] ## Disclaimer This guide is for educational purposes based on historical program data as of 2024. Oxbryta is **no longer available** due to voluntary withdrawal for safety reasons – do not start or continue without provider guidance. Assistance programs change; visit pfizerrxpathways.com or call Pfizer for updates (inactive for Oxbryta). Not medical advice – consult your doctor. Income/FPL figures approximate; verify officially. Word count: 942.

Program information last verified: March 30, 2026